Editorial: Hemophilia, cancer and cardiovascular disease

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 1, 2010, Pages 1-2

  Franchini, Massimo ^a   Favaloro, Emmanuel J ^b   Lippi, Giuseppe ^c  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

CARDIOVASCULAR DISEASE; EDITORIAL; HEMOPHILIA; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOCOAGULABILITY; ISCHEMIC HEART DISEASE; LIFESPAN; LYMPHOMA; NEOPLASM; PRIORITY JOURNAL; ANIMAL; CANADA; CAUSE OF DEATH; COMORBIDITY; EUROPE; FEMALE; HEMOPHILIA A; HUMAN; MALE; MORTALITY; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CANADA; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; EUROPE; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; MALE; MICE; NEOPLASMS;

EID: 75649106511     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832da19a     Document Type: Editorial

References (14)

1. Mannucci PM, Tuddenham EG. The hemophilias: from royal genes to gene therapy. N Engl J Med 2001; 344:1773-1779.
2. Mejia-Carvajal C, Czapek EE, Valentino LA. Life expectancy in hemophilia outcome. J Thromb Haemost 2006; 4:507-509.
3. Soucie JM, Nuss R, Evatt B, Abdelhak A, Cowan L, Hill H, et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000; 96:437-442.
4. Franchini M, Tagliaferri A, Mannucci PM. The management of hemophilia in elderly patients. Clin Interv Aging 2007; 2:361-368.
5. Walker IR, Julian JA. Causes of death in Canadians with haemophilia 1980- 1995. Association of Hemophilia Clinic Directors of Canada. Haemophilia 1998; 4:714-720.
6. Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110:815-825.
7. Plug I, Van Der Bom JG, Peters M, Mauser-Bunschoten EP, De Goede- Bolder A, Heijnen L, et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. Thromb Haemost 2006; 4:510-516.
8. Brüggemann LW, Versteeg HH, Niers TM, Reitsma PH, Spek CA. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med 2008; 12:2622-2627.
9. Langer F, Amirkhosravi A, Ingersoll SB, Walker JM, Spath B, Eifrig B, et al. Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost 2007; 4:1056-1062.
10. Berntorp E, Salvagno GL. Standardization and clinical utility of thrombingeneration assays. Semin Thromb Haemost 2008; 34:670-682.
11. Koumbarelis E, Rosendaal FR, Gialeraki A, Karafoulidou A, Noteboom WM, Loizou C, et al. Epidemiology of haemophilia in Greece: an overview. Thromb Haemost 1994; 72:808-813.
12. Triemstra M, Rosendaal FR, Smit C, van der Ploeg HM, Briet E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995; 123:823-827.
13. Šrámek A, Kriek M, Rosendaal FR. Decreased mortality of ischemic heart disease among carriers of hemophilia. Lancet 2003; 362:351-354.
14. Kiechl S, Willeit J. Cardiovascular protection in haemophilia. Lancet 2003; 362:2026.